- Home
- TTNP vs EYEN Comparison
TTNP vs EYEN Comparison
Compare TTNP & EYEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTNP
- EYEN
- Stock Information
- Founded
- TTNP 1991
- EYEN 2014
- Country
- TTNP United States
- EYEN United States
- Employees
- TTNP N/A
- EYEN N/A
- Industry
- TTNP Biotechnology: Biological Products (No Diagnostic Substances)
- EYEN Biotechnology: Pharmaceutical Preparations
- Sector
- TTNP Health Care
- EYEN Health Care
- Exchange
- TTNP Nasdaq
- EYEN Nasdaq
- Market Cap
- TTNP 3.4M
- EYEN 2.9M
- IPO Year
- TTNP 1996
- EYEN 2018
- Fundamental
- Price
- TTNP $4.67
- EYEN $1.13
- Analyst Decision
- TTNP
- EYEN Hold
- Analyst Count
- TTNP 0
- EYEN 4
- Target Price
- TTNP N/A
- EYEN $2.00
- AVG Volume (30 Days)
- TTNP 42.9K
- EYEN 54.4K
- Earning Date
- TTNP 05-27-2025
- EYEN 05-23-2025
- Dividend Yield
- TTNP N/A
- EYEN N/A
- EPS Growth
- TTNP N/A
- EYEN N/A
- EPS
- TTNP N/A
- EYEN N/A
- Revenue
- TTNP N/A
- EYEN $57,336.00
- Revenue This Year
- TTNP N/A
- EYEN $7,680.45
- Revenue Next Year
- TTNP N/A
- EYEN $315.38
- P/E Ratio
- TTNP N/A
- EYEN N/A
- Revenue Growth
- TTNP N/A
- EYEN 1414.02
- 52 Week Low
- TTNP $3.03
- EYEN $0.85
- 52 Week High
- TTNP $14.80
- EYEN $124.80
- Technical
- Relative Strength Index (RSI)
- TTNP 57.83
- EYEN 47.32
- Support Level
- TTNP $4.52
- EYEN $1.02
- Resistance Level
- TTNP $5.10
- EYEN $1.24
- Average True Range (ATR)
- TTNP 0.50
- EYEN 0.09
- MACD
- TTNP 0.07
- EYEN 0.02
- Stochastic Oscillator
- TTNP 49.77
- EYEN 44.00
About TTNP Titan Pharmaceuticals Inc.
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical-stage ophthalmic company developing a pipeline of therapeutics based on its proprietary array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Optejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies that target new indications or new combinations.